PRWeb The Leader Press Release Distribution

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for April 28, 2004 Subscribe to this News Feed    
 

Genstruct Adopts Ariadne Genomics MedScan TextMiner For Discovery Platform Development

Ariadne Genomics, Inc. today announced the selection of its MedScan TextMiner software by Genstruct Inc. (Cambridge, MA) as an aid in the development of their Molecular Epistemics discovery platform. MedScan TextMiner enables automated extraction of biological facts from scientific literature. Genstruct will use this software to improve the efficiency and output of their Knowledge Assembly process, which results in precise, logical models of biology that are used to identify compound mechanism of action (MOA) and disease mechanisms.

ROCKVILLE, MD (PRWEB) April 28, 2004 --Ariadne Genomics, Inc. today announced the selection of its MedScan TextMiner software by Genstruct Inc. (Cambridge, MA) as an aid in the development of their Molecular Epistemics discovery platform. MedScan TextMiner enables automated extraction of biological facts from scientific literature. Genstruct will use this software to improve the efficiency and output of their Knowledge Assembly process, which results in precise, logical models of biology that are used to identify compound mechanism of action (MOA) and disease mechanisms.

The accuracy of our assertions is one of our highest priorities," commented Keith O. Elliston, Ph.D., President and CEO of Genstruct. MedScan TextMiner, with its unique Natural Language Processing engine, will improve our ability to apply Knowledge Assembly to the extraction of molecular interaction information from the scientific literature."

Genstruct chose to use Ariadne Genomics MedScan TextMiner because it is a simple, powerful tool that provides reliable data in a user-friendly XML format", said Ilya Mazo, President of Ariadne Genomics. With MedScan, Genstruct can expand its knowledge base and provide more comprehensive information to its biotechnology and pharmaceutical research partners."

For more information about MedScan Text Miner, call (240) 453-6296, or visit the Ariadne Genomics web site at www.ariadnegenomics.com.

About Ariadne Genomics
Ariadne Genomics provides software tools and knowledge bases for systems biology, based on its innovative Natural Language Processing (NLP) technology and statistical algorithms: PathwayAssist for visualization and analysis of cell regulatory pathways, MedScan, an automated data mining tool for scientific literature (MEDLINE abstracts), DiscoveryCore, a super fast scientific database management system, DAS Browser for navigation and analysis of completely sequenced genomes, and ResNet, a comprehensive database of molecular networks, derived from MEDLINE data. More on Ariadne Genomics please find at www.ariadnegenomics.com.

About Genstruct
Genstruct, founded in 2001, has developed a platform for the discovery and definition of compound mechanism of action (MOA) and biomarkers called Molecular Epistemics. The platform comprises a suite of patent pending technologies that model and analyze compound MOA: the Knowledge Assembly process which enables rapid, ongoing construction of an addressable biological knowledgebase; and a set of tools for mining and refining the knowledgebase including the Epistemics Engine process for pathway discovery and validation. Genstruct is developing discovery and development partnerships that apply the Molecular Epistemics platform to accelerate and increase the output of drug discovery and development programs. The Company was co-founded by Flagship Ventures, based in Cambridge, MA. For more information please visit www.genstruct.com.

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Natalia Alexandrova
ARIADNE GENOMICS
847 644 1557
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appearshere.